Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysis
Year: 2025
Type: article
Study design: Observational Study
Abstract: Purpose [ 68 Ga]Ga-FAPI-46 has shown promise for urothelial cancer (UC) detection. This study evaluates its diagnostic value versus contrast-enhanced CT (ceCT) and 2-[ 18 F]FDG PET in the largest bi-centric cohort to date. Methods Patients with metastatic UC undergoing [ 68 Ga]Ga-FAPI-46 PET at University Hospitals Munich or Essen were retrospectively reviewed. Detection rates were compared with ceCT on a regional basis (primary, lymph nodes, visceral organs, bone). SUV max and SUV mean of two index lesions were recorded. In a sub-cohort, [ 68 Ga]Ga-FAPI-46 and 2-[ 18 F]FDG PET were compared on a lesion basis. Clinical follow-up and/or histopathology served as reference. Results Thirty-four patients underwent [ 68 Ga]Ga-FAPI-46 PET/CT and ceCT, including 10 (29%) with additional 2-[ 18 F]FDG PET/CT. Across 98 lesions ( n = 65 regions), [ 68 Ga]Ga-FAPI-46 PET detected n = 96 (98%) and ceCT n = 88 (90%), with mismatch findings in eight lymph nodes (PET positive/ceCT negative) and two visceral organs (ceCT positive/PET negative). In the subgroup comparison, 78 lesions were detected in total ([ 68 Ga]Ga-FAPI-46: n = 72 (92%); 2-[ 18 F]FDG: n = 78 (100%)). Tumour uptake was comparable (SUV max [ 68 Ga]Ga-FAPI-46 PET vs. 2-[ 18 F]FDG: 10.2 (IQR, 1.9) vs. 8.0 (IQR, 3.3), p = 0.249), whereas [ 68 Ga]Ga-FAPI-46 provided higher tumour-to-background ratios (Tumour-to-liver: 12.7 (IQR, 10.3) vs. 3.8 (IQR, 1.9), p = 0.046; tumour-to-spleen: 8.4 (IQR, 6.6) vs. 4.6 (IQR, 0.6), p = 0.016). Conclusion [ 68 Ga]Ga-FAPI-46 PET demonstrated higher regional detection rates than ceCT in UC patients, particularly for lymph node metastases. Compared to 2-[ 18 F]FDG, it provided superior tumour-to-background contrast but detected slightly fewer lesions. [ 68 Ga]Ga-FAPI-46 PET may complement established imaging in selected scenarios, although its role in routine UC staging remains investigational.
Authors: Kim M. Pabst, Sophie C. Siegmund, Adrien Holzgreve, Hans P. Schmid, Timo Bartel, Ken Herrmann, Alina T. Küper, Can Aydogdu, David Kersting, Claudia Kesch, Boris A. Hadaschik, Marcus Unterrainer, Christian G. Stief, Clemens C. Cyran, Rudolf A. Werner, Wolfgang P. Fendler, Jozefina Casuscelli, Lena M. Unterrainer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,490
OpenAlex ID: W4416664033
